BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)

This is a sentiment-only input, so the tradable signal is mostly in the marginal flow it can create rather than any change to fundamentals. BR is the cleaner quality/defensive compounder story; if the market is already crowded into cash-generative financial infrastructure, the upside from this kind of recognition is usually limited to a short-lived multiple nudge, not a durable rerate. RMD is more interesting because “undervalued” can reinforce a valuation floor if investors are already debating whether the growth engine is intact versus GLP-1 headwinds.

The second-order read is that a positive framing on RMD is implicitly a bearish relative signal for alternative sleep-apnea exposure such as INSP, where the market has been paying for a disruption narrative. If RMD continues to print stable volume growth and the feared demand destruction fails to show up in forward guidance, the stock can outperform over 1-3 months even without a major multiple expansion. The reverse is also true: any earnings or commentary that confirms slower prescription growth would quickly invalidate the thesis, because the article itself has no hard data behind it.

Contrarian view: these editorial labels often lag price and can become a source of liquidity for sellers rather than a catalyst for new demand. The more likely outcome is a modest, temporary relative-strength trade in RMD and almost no durable impact in BR unless the next earnings print confirms the narrative. In other words, this is a watch item, not a conviction event.